Nektar Therapeutics Stock Forecast, Price & News

-0.33 (-2.03 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume898,946 shs
Average Volume1.07 million shs
Market Capitalization$2.90 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Nektar Therapeutics logo

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company that focuses on discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and auto-immune disease. The company was founded in 1990 and is headquartered in San Francisco, CA.


NKTR Jul 2021 26.000 call
NKTR Jul 2021 26.000 call
July 16, 2021 |
NKTR Jul 2021 21.000 call
NKTR Jul 2021 21.000 call
July 15, 2021 |
Nektar Therapeutics Common Stock (NKTR)
Nektar Therapeutics Common Stock (NKTR)
July 15, 2021 |
NKTR Jul 2021 15.000 call
NKTR Jul 2021 15.000 call
July 14, 2021 |
NKTR Jul 2021 19.000 call
NKTR Jul 2021 19.000 call
July 8, 2021 |
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up to $16.91
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up to $16.91
July 7, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.83 out of 5 stars

Medical Sector

329th out of 2,218 stocks

Pharmaceutical Preparations Industry

153rd out of 869 stocks

Analyst Opinion: 3.2Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

Is Nektar Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Nektar Therapeutics?

Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nektar Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Nektar Therapeutics

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.04. The biopharmaceutical company earned $23.60 million during the quarter, compared to analysts' expectations of $26.15 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 38.12% and a negative net margin of 340.31%. The company's revenue for the quarter was down 53.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.78) EPS.
View Nektar Therapeutics' earnings history

How has Nektar Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NKTR shares have decreased by 3.4% and is now trading at $15.91.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NKTR?

6 Wall Street analysts have issued twelve-month price objectives for Nektar Therapeutics' shares. Their forecasts range from $20.00 to $26.00. On average, they expect Nektar Therapeutics' share price to reach $24.20 in the next year. This suggests a possible upside of 52.1% from the stock's current price.
View analysts' price targets for Nektar Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Howard W. Robin, President, Chief Executive Officer & Director
  • Gilbert M. Labrucherie, Chief Operating & Financial Officer
  • Jonathan Zalevsky, Chief Research & Development Officer
  • Dimitry S. A. Nuyten, Chief Medical Officer & Senior Vice President
  • Mark A. Wilson, Secretary, Senior Vice President & General Counsel

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Oregon Public Employees Retirement Fund (0.03%) and New Mexico Educational Retirement Board (0.02%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was bought by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Nektar Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $15.91.

How much money does Nektar Therapeutics make?

Nektar Therapeutics has a market capitalization of $2.90 billion and generates $152.91 million in revenue each year. The biopharmaceutical company earns $-444,440,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics employs 718 workers across the globe.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is

Where are Nektar Therapeutics' headquarters?

Nektar Therapeutics is headquartered at 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at (415) 482-5300 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.